Title: Cost-Effectiveness Analysis Of Obinutuzumab/Chlorambucil Vs Rituximab/Chlorambucil In Treatment Of Chronic Lymphocytic Leukemia
Abstract: To conduct a cost-effectiveness assessment of obinutuzumab/chlorambucil (G-Clb) vs rituximab/chlorambucil (R-Clb) in treatment of chronic lymphocytic leukemia (1st line treatment) among elderly patients with coexisting conditions in the Russian Federation. To conduct present study there was developed a special model (time horizon – 36 months). All necessary data was obtained from CLL 11. Effectiveness analysis was based on the following criteria – number of life years. Cost analysis included only direct costs on the treatment of CLL (1st line: G-Clb or R-Clb, 2nd and 3rd lines – Bendamustin-Rituximab) and severe adverse events. Cost data was based on median prices for medicines and medical services in National healthcare system in the Russian Federation. Total costs per patient in the group of G-Clb were 3217189 rubbles (€ 59688) and for R-Clb - 3102020 rubbles (€ 57552). The number of life years for G-Clb was 2,88 and for R-Clb - 2,75. Cost-effectiveness ratio for G-Clb was 1116724 (€ 20719) and for R-Clb was 1129204 rubbles (€ 20950). Due to the lower cost-effectiveness ratio, the use of G-Clb instead of R-Clb in treatment of CLL among elderly patients with coexisting conditions in the Russian Federation is more reasonable from a pharmacoeconomic point of view.